| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1031: Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over |
|
Medicine details |
|
| Medicine name | vamorolone |
| Formulation | oral suspension |
| Reference number | 5252 |
| Indication | Treating inflammation associated with Duchenne muscular dystrophy |
| Company | Santhera Pharmaceuticals |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/03/2023 |
| NICE guidance | TA1031: Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over |